Momenta Phama (MNTA) Prices 14.516M Share Common Offering at $15.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
December 12, 2019 8:00 AM ESTCAMBRIDGE, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of its underwritten public offering of 14,516,130 shares of its common stock at the public offering price of $15.50 per share for total gross proceeds to Momenta of approximately $225.0 million. Momenta has granted the underwriters an option to purchase up to an additional 2,177,419 shares of its common stock, exercisable for 30 days.Â
Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering. Stifel is acting as a book-running manager for the... More



